Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE -related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting
Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C.
Emendo presented pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of Emendo’s dual technology platforms that enable the development of a highly specific editing composition that demonstrates no off-targets and complete allele specificity. Significantly, the lack of off-target achieved by Emendo’s engineered and optimized OMNI nuclease also eliminated any translocations. Edited patient derived CD34+ cells differentiated normally into neutrophils both in-vitro and in-vivo, showing full engraftment and reconstitution of all blood lineages, as required for the desired therapeutic effect.
“ELANE-based Severe Congenital Neutropenia, Emendo’s lead indication, is a devastating disease affecting pediatric patients that until now has been incurable,” said David Baram, Ph.D., President & CEO of Emendo Biotherapeutics. “We are excited by the potentially curative treatment developed by our team and were pleased to present our pre-clinical results for this program and other diverse applications of our dual gene editing technology platforms at this year’s ASGCT meeting. And of course, we look forward to the discussion generated by our discoveries around Type II CRISPR nuclease classifications that promise to be ground-breaking in the field.”
Senior members of the Emendo Biotherapeutics R&D team including Chief Technology Officer Lior Izhar, Ph.D. and Executive Vice-President Research & Development Rafi Emmanuel, Ph.D. presented Emendo’s research on-site at the conference.
Session Presentation
Title: A Novel Engineered CRISPR-Associated Nuclease Accurately Removes ELANE Mutated Allele and Shifts HSC Differentiation Towards Neutrophils in Severe Congenital Neutropenia
Session Title: Gene Therapy for Immunologic Diseases
Session Date/Time: Tuesday May 17, 2022 3:45 PM - 5:30 PM
Presentation Time: 3:45pm - 4:00pm
Room: Room 202
Final abstract number: 482
Poster Presentations
Title: A Unique CRISPR-Based Nuclease with a Non-NGG PAM Efficiently Targets Multiple Exclusive Genomic Sites for Immuno-Oncology Based Therapy
Session Title: Cancer - Targeted Gene and Cell Therapy I
Session Date/Time: Monday May 16, 2022 5:30 PM - 6:30 PM
Poster Board Number: M-215
Room: Hall D
Final abstract number: 334
Title: CRISPR-Based Gene Editing Enhances LDLR Expression and Boosts LDL-C Uptake in Familial Hypercholesterolemia
Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases II
Session Date/Time: Wednesday May 18, 2022 5:30 PM - 6:30 PM
Poster Board Number: W-125
Room: Hall D
Final abstract number: 999
Title: Challenges and Inconsistencies in Type II CRISPR-Associated Nuclease Subtype Classification
Session Title: Gene Targeting and Gene Correction II
Session Date/Time: Tuesday May 17, 2022 5:30 PM - 6:30 PM
Poster Board Number: Tu-61
Room: Hall D
Final abstract number: 556
About Emendo Biotherapeutics
Emendo Biotherapeutics, a subsidiary of AnGes, Inc., is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. Emendo’s novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide Emendo with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas. For more information please visit www.emendobio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006030/en/
Contact information
Media:
Shahar Avni
Business Development Specialist
shahara@emendobio.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Enters into Exclusive Talks to Acquire Invoke30.5.2023 08:19:00 CEST | Press release
Regnology, a leading software provider with a focus on regulatory reporting solutions, announces today it expects to sign a definitive agreement to acquire Invoke, a French-based provider of financial, regulatory, and tax reporting solutions for supervisory authorities, and reporting entities. On completion of the agreement, the deal would mark the fifth acquisition in less than a year for Regnology. With 160+ full-time employees, Invoke serves over 1,800 regulated entities and supervisory authorities throughout Europe with its XBRL-based banking, insurance, and tax reporting solutions. Invoke’s corporate tax solution will complement Regnology’s financial tax reporting solution and open a new growth area for the company. Rob Mackay, CEO of Regnology, comments: “The round of recent deals we have undertaken, culminating with today’s announcement, sets Regnology on an accelerated path for growth internationally. Invoke’s advanced solutions would complement our technology stack while its t
William O'Neil + Company Announces the Passing of William J. O'Neil30.5.2023 05:21:00 CEST | Press release
William J. O'Neil, "Bill," a highly accomplished figure in the world of stock speculation, entrepreneurship, authorship, and philanthropy has passed away at the age of 90. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230529005167/en/ William J. O'Neil (Photo: Business Wire) Bill exemplified the American spirit and firmly believed that through hard work, anyone could attain prosperity. His approach to success was characterized by his willingness to challenge conventional wisdom, carefully analyze the data, and follow it wherever it led him, on his own terms. With humble beginnings, he became the youngest person to purchase a seat on the New York Stock Exchange at 30 years old. He wrote several best-selling books sharing the investment methodologies he built his businesses upon and devoted much of his life to extending a path toward financial freedom for all. He was a vocal proponent of a free enterprise system and its contr
Huawei ICT Competition 2022-2023 Global Final Held in Shenzhen — 146 Teams from 36 Countries and Regions Win Awards30.5.2023 04:54:00 CEST | Press release
On May 27, 2023, the Huawei ICT Competition 2022-2023 Global Final concluded in Shenzhen, drawing to a close the seventh installment of this competition. The first to be held in person since 2019, the event’s culmination was a competition between finalists in 146 teams from 36 countries. Before the Final, more than 120,000 students from more than 2000 universities in 74 countries and regions around the world took part in the ICT Competition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230529005085/en/ Huawei ICT Competition 2022–2023 Global Final Closing and Awarding Ceremony (Photo: Huawei) Teams from Shenzhen Polytechnic, Guilin University of Electronic Technology, Guangzhou College of Commerce, Yangtze Normal University, and Hunan Industry Polytechnic won the Network Track Grand Prize. Teams from Guilin University of Electronic Technology, Shenzhen Polytechnic, and Nanning College for Vocational Technology won the Clou
Tourists from Four Asian Countries and Regions Can Now Pay in Thailand with Mobile Wallets30.5.2023 04:21:00 CEST | Press release
Ant Group, the operator of Alipay+, the global cross-border digital payments and marketing solution today announced that a total of four mobile wallets are now accepted in Thailand. These include AlipayHK (Hong Kong SAR), Kakao Pay (South Korea), Touch ‘n Go eWallet (Malaysia) and Alipay (Chinese mainland), which has been accepted by Thai merchants since 2015. Enabled through Alipay+, the latest development and the addition of three more mobile wallets will expand the seamless digital travel experience for more Asian tourists visiting Thailand, in the midst of a rapid rebound in the local tourism industry. Ant Group also unveiled new collaborations with the Tourism Authority of Thailand (“TAT”), to promote the Amazing Thailand campaign and to stimulate travel in Thailand. In addition to facilitating purchases and transactions made by mobile wallets familiar to tourists, Ant Group will also provide digital solutions to local businesses in areas such as digitalisation of service operatio
TYAN Accelerates AI, HPC, Cloud, Storage Workloads With New Platforms Featuring 4 th Gen Intel Xeon Scalable Processors at Computex 202330.5.2023 02:00:00 CEST | Press release
TYAN®, an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, showcases its latest HPC, cloud and storage platforms at Computex 2023, Booth #M0701a in Taipei, Taiwan from May 30 to June 2. These platforms are powered by 4th Gen Intel Xeon Scalable processors, which highlight built-in accelerators to improve performance across the fastest-growing workloads in AI, analytics, cloud, storage, and HPC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230529005003/en/ TYAN's new server platforms accelerate computing and AI inferencing workflows with 4th Gen Intel Xeon Scalable processors (Photo: Business Wire) "As organizations seek to scale up, drive down costs, and deliver new services, it's more critical than ever for technology to deliver business value," said Eric Kuo, Vice President of the Server Infrastructure Business Unit at MiTAC Computing Technology Corporation.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom